Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).

J Gynecol Oncol · 2023 · PMC9995864 · PMID 36659832

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

From molecular analysis of portec-3 trial, p53abn subgroup had a highly significant benefit from CTRT with an absolute benefit of 22.4% and 23.1% for 5-year RFS and OS, compared with radiotherapy alone [ 6 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.